AR008886A1 - Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea - Google Patents

Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea

Info

Publication number
AR008886A1
AR008886A1 ARP970104655A ARP970104655A AR008886A1 AR 008886 A1 AR008886 A1 AR 008886A1 AR P970104655 A ARP970104655 A AR P970104655A AR P970104655 A ARP970104655 A AR P970104655A AR 008886 A1 AR008886 A1 AR 008886A1
Authority
AR
Argentina
Prior art keywords
manufacture
inhibitor
pharmaceutical formulation
treatment
widal
Prior art date
Application number
ARP970104655A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR008886A1 publication Critical patent/AR008886A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de un inhibidor de H+,K+ -ATPasa en la fabricacion de un medicamento para el tratamiento de polipos nasales que comprende una cantidad efectiva dedicho inhibidor y un vehículo farmacéuticamente aceptable, uso de dicho inhibidor para la fabricacion de un medicamento para el tratamiento delsíndrome de Widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmacéutica y formulacion farmacéutica paraadministracion simultánea.
ARP970104655A 1996-10-11 1997-10-08 Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea AR008886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment

Publications (1)

Publication Number Publication Date
AR008886A1 true AR008886A1 (es) 2000-02-23

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104655A AR008886A1 (es) 1996-10-11 1997-10-08 Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea

Country Status (34)

Country Link
EP (1) EP0946175B1 (es)
JP (1) JP4100713B2 (es)
KR (1) KR100510812B1 (es)
CN (1) CN1146416C (es)
AR (1) AR008886A1 (es)
AT (1) ATE230597T1 (es)
AU (1) AU738310B2 (es)
BR (1) BR9711896A (es)
CA (1) CA2268305C (es)
CZ (1) CZ298799B6 (es)
DE (1) DE69718347T2 (es)
DK (1) DK0946175T3 (es)
EE (1) EE04043B1 (es)
ES (1) ES2188995T3 (es)
HK (1) HK1022848A1 (es)
HU (1) HUP0000036A3 (es)
ID (1) ID23692A (es)
IL (1) IL129324A0 (es)
IS (1) IS1930B (es)
MY (1) MY117918A (es)
NO (1) NO321007B1 (es)
NZ (1) NZ334786A (es)
PL (1) PL190902B1 (es)
PT (1) PT946175E (es)
RS (1) RS49599B (es)
RU (1) RU2197966C2 (es)
SA (1) SA97180641B1 (es)
SE (1) SE9603725D0 (es)
SK (1) SK284252B6 (es)
TR (1) TR199900770T2 (es)
TW (1) TW568784B (es)
UA (1) UA59374C2 (es)
WO (1) WO1998016228A1 (es)
ZA (1) ZA978842B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
WO2000010588A2 (en) 1998-08-18 2000-03-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
CA2467652A1 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
CA2478958A1 (en) * 2002-03-14 2003-09-18 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
NZ536918A (en) * 2002-05-07 2006-09-29 Altana Pharma Ag Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases
BR0309808A (pt) * 2002-05-07 2005-03-01 Altana Pharma Ag Combinação para o tratamento de distúrbios das vias aéreas
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
DE60323138D1 (de) 2002-12-12 2008-10-02 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PT1670482E (pt) 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
EP0946175B1 (en) 2003-01-08
CN1232397A (zh) 1999-10-20
KR20000049046A (ko) 2000-07-25
WO1998016228A1 (en) 1998-04-23
NO991619D0 (no) 1999-04-06
KR100510812B1 (ko) 2005-08-31
PL332692A1 (en) 1999-09-27
TW568784B (en) 2004-01-01
HUP0000036A3 (en) 2003-02-28
NZ334786A (en) 2000-12-22
HU0000036D0 (es) 2002-05-29
ID23692A (id) 2000-05-11
CZ122999A3 (cs) 1999-09-15
PL190902B1 (pl) 2006-02-28
MY117918A (en) 2004-08-30
AU4640997A (en) 1998-05-11
ATE230597T1 (de) 2003-01-15
EE04043B1 (et) 2003-06-16
EP0946175A1 (en) 1999-10-06
RU2197966C2 (ru) 2003-02-10
CZ298799B6 (cs) 2008-02-06
JP4100713B2 (ja) 2008-06-11
DE69718347T2 (de) 2003-08-28
RS49599B (sr) 2007-06-04
IL129324A0 (en) 2000-02-17
TR199900770T2 (xx) 1999-06-21
JP2001508034A (ja) 2001-06-19
NO321007B1 (no) 2006-02-27
ES2188995T3 (es) 2003-07-01
PT946175E (pt) 2003-04-30
HK1022848A1 (en) 2000-08-25
ZA978842B (en) 1998-04-14
EE9900118A (et) 1999-10-15
DE69718347D1 (de) 2003-02-13
CN1146416C (zh) 2004-04-21
SK284252B6 (sk) 2004-12-01
SA97180641B1 (ar) 2005-12-18
AU738310B2 (en) 2001-09-13
NO991619L (no) 1999-04-06
UA59374C2 (uk) 2003-09-15
IS1930B (is) 2004-05-18
CA2268305C (en) 2006-11-28
SE9603725D0 (sv) 1996-10-11
HUP0000036A2 (hu) 2002-05-29
IS5021A (is) 1999-04-08
SK38499A3 (en) 2000-03-13
YU16399A (sh) 2000-03-21
BR9711896A (pt) 1999-08-24
CA2268305A1 (en) 1998-04-23
DK0946175T3 (da) 2003-03-17

Similar Documents

Publication Publication Date Title
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
AR035500A1 (es) Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina.
HRP20020837B1 (en) Hormone replacement therapy
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
NZ288298A (en) Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
AP2003002922A0 (en) Skin-permeable selective cyclooxygenase-2 inhibitor composition.
SE0003449D0 (sv) Anticancer compositions
SE9702533D0 (sv) New oral formulation
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
ATE287699T1 (de) Pharmazeutische aerosolzusammensetzungen
AU2084801A (en) Antiviral medication
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR039408A1 (es) Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
BR9709316A (pt) Composição farmacêutica para administração tópica no tratamento da vaginite
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
AR017455A1 (es) Composiciones farmaceuticas que comprenden (1s,4r)-cis-4-[2-amino-6-ciclopropilamino)-9h-purin-9-ilo]-2-ciclopenten-1-metanol, un quelante de metal y un agente edulcorante
ATE295169T1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist
DE69228686D1 (de) Topisch anzuwendendes arzneimittel enthaltend penciclovir

Legal Events

Date Code Title Description
FB Suspension of granting procedure